Global Imipenem Astatin Sodium for Injection Market Outlook:
The future outlook for the Global Imipenem Astatin Sodium for Injection Market is promising, as per a recent survey. The market, which was valued at US$ 2400 million in 2022, is projected to grow to US$ 3561 million by 2029. This represents a Compound Annual Growth Rate (CAGR) of 5.8% during the period from 2023 to 2029. This growth projection indicates a steady demand for Imipenem Astatin Sodium injections over the forecast period. The growth can be attributed to various factors, including the increasing prevalence of bacterial infections, the growing resistance of bacteria to other antibiotics, and the ongoing efforts to improve access to effective antibiotics worldwide. However, the market's growth might be influenced by various challenges, including regulatory hurdles, production costs, and competition from other antibiotics. NO DATA
| Report Metric | Details |
| Report Name | Imipenem Astatin Sodium for Injection Market |
| Accounted market size in 2022 | US$ 2400 million |
| Forecasted market size in 2029 | US$ 3561 million |
| CAGR | 5.8% |
| Base Year | 2022 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | MSD, Shandong New Era Pharmaceuticals, Shenzhen Haibin Pharmaceutical, Sinopharm Guorui Pharmaceutical, Merck Sharp & Dohme Corp., Taiwan Biotech Co., Ltd., Sun Pharmaceutical Industries Ltd., JW PHARMACEUTICAL CORPORATION, Gentle Pharma Co.,Ltd. |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
